Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0NC9M
|
|||
| Drug Name |
CM-CS1 T-cell
|
|||
| Drug Type |
CAR T Cell Therapy
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60] | Phase 1 | [1] | |
| Multiple myeloma [ICD-11: 2A83; ICD-10: C90.0] | Phase 1 | [1] | ||
| Myelodysplastic syndrome [ICD-11: 2A37; ICD-9: 238.7] | Phase 1 | [1] | ||
| Company |
Celyad (formerly named Cardio3 BioSciences)
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | NKG2 D activating NK receptor (KLRK1) | Target Info | CAR-T-Cell-Therapy | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02203825) Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.